MAR 31, 2020 6:28 AM PDT

Ovarian cancer metastasis and CPT1A

Research published in the journal Molecular Cancer Research from collaborators at the University of Colorado Cancer Center hits on new insight as to how ovarian cancer spreads. While ovarian cancer grows in the fallopian tubes, in order to spread it must depend on an energy source. The researchers have discovered that ovarian cancer cells rely on cells with high-fat content to garner the energy to metastasize and that a specific enzyme CPT1A allows them to do so. This discovery provides an opportunity to target CPT1A in order to slow the spread of ovarian cancer cells, a realization that could open new paths for future treatment options.

Benjamin Bitler, Ph.D., from the CU Cancer Center, explains that he and his colleagues observed how the enzyme CPT1A controls how much fat ovarian cancer cells can burn. From there, they hypothesized that limiting cells' access to CPT1A could cut off the energy supply they need to spread.

Referring to ovarian cancer cells, Bitler says, "When they break off, they metabolically shift to use fats more - it allows these cells to survive and then they seek out or are able to colonize fatty tissue. It looked like CPT1A was the rate-limiting step in their ability to do this," says Bitler, who is also an assistant professor in the CU School of Medicine Department of Obstetrics & Gynecology.

Bitler worked with colleague Isabel Schlaepfer, Ph.D. to further understand the role of CPT1A. Together, they showed that the presence of the enzyme prevented ovarian cancer cells from dying, while the lack of the enzyme significantly reduced the spread of human cancer cells grown in mouse models. "It didn't completely abolish ovarian cancer cells' capacity to go to fat-rich sites, but it reduced it pretty dramatically," says Bitler.

The researchers are working to move this discovery out of the laboratory and into clinical trials. "There's a drug called etomoxir that inhibits CPT1A and has been tested as a preventative for congestive heart failure," Bitler says. "Our hope is that we could use etomoxir to treat chemo-resistant disease," Bitler says.

Sources: Molecular Cancer Research, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
APR 01, 2020
Cancer
APR 01, 2020
New immunotherapy for ovarian cancer
Research published recently in the Journal of Experimental Medicine suggests that targeting macrophages in a new kind of ...
MAY 01, 2020
Cancer
MAY 01, 2020
Cancer patients' high mortality from COVID-19
A study published today in the online edition of Cancer Discovery reports that people with cancer who develop COVID-19 a ...
MAY 11, 2020
Cancer
MAY 11, 2020
Using Deep Learning to Diagnose Breast Cancer Sub-Types
Cancer and computer programming may not sound like two things that go together. However, advanced programming techniques ...
MAY 06, 2020
Cancer
MAY 06, 2020
Olanzapine useful for cancer patients managing nausea unrelated to chemo
A study published last week in JAMA Oncology reports that a generic drug called Olanzapine could be useful for cancer pa ...
MAY 14, 2020
Cancer
MAY 14, 2020
New hope for immunotherapy for pediatric brain cancer
Pediatric brain cancer is an especially tough pill to swallow. While one in four children does not survive medulloblasto ...
MAY 23, 2020
Cancer
MAY 23, 2020
Can metformin treat lymphoma?
A popular diabetes medication may be useful in treating cancer, according to new research published recently in Cell Rep ...
Loading Comments...